Correlation Between IBio, Common and Virax Biolabs

Can any of the company-specific risk be diversified away by investing in both IBio, Common and Virax Biolabs at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining IBio, Common and Virax Biolabs into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between iBio, Common Stock and Virax Biolabs Group, you can compare the effects of market volatilities on IBio, Common and Virax Biolabs and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in IBio, Common with a short position of Virax Biolabs. Check out your portfolio center. Please also check ongoing floating volatility patterns of IBio, Common and Virax Biolabs.

Diversification Opportunities for IBio, Common and Virax Biolabs

-0.72

Correlation Coefficient

IBio, Common  Virax Biolabs

Pay attention - limited upside

The 3 months correlation between IBio, and Virax is -0.72. Overlapping area represents the amount of risk that can be diversified away by holding iBio, Common Stock and Virax Biolabs Group in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Virax Biolabs Group and IBio, Common is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on iBio, Common Stock are associated (or correlated) with Virax Biolabs. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Virax Biolabs Group has no effect on the direction of IBio, Common i.e., IBio, Common and Virax Biolabs go up and down completely randomly.

Pair Corralation between IBio, Common and Virax Biolabs

Given the investment horizon of 90 days iBio, Common Stock is expected to generate 1.02 times more return on investment than Virax Biolabs. However, IBio, Common is 1.02 times more volatile than Virax Biolabs Group. It trades about 0.17 of its potential returns per unit of risk. Virax Biolabs Group is currently generating about -0.09 per unit of risk. If you would invest  245.00  in iBio, Common Stock on December 27, 2024 and sell it today you would earn a total of  196.00  from holding iBio, Common Stock or generate 80.0% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

iBio, Common Stock  vs.  Virax Biolabs Group

iBio, Common Stock

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in iBio, Common Stock are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of very weak forward indicators, IBio, Common displayed solid returns over the last few months and may actually be approaching a breakup point.

Virax Biolabs Group

Risk-Adjusted Performance

Very Weak

Over the last 90 days Virax Biolabs Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with IBio, Common and Virax Biolabs

The main advantage of trading using opposite IBio, Common and Virax Biolabs positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if IBio, Common position performs unexpectedly, Virax Biolabs can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Virax Biolabs will offset losses from the drop in Virax Biolabs' long position.

The idea behind iBio, Common Stock and Virax Biolabs Group pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.